Distant metastases cause more than 90% of cancer-related mortality. Children suffering from osteosarcoma, where the typical route of spread is from bone to lung, are no exception. Despite the development of numerous treatment modalities targeting the primary tumor, 40% of patients still die from metastatic progression. There is therefore a pressing clinical need to determine the factors responsible for lung metastasis in osteosarcoma to facilitate development of novel anti- metastatic therapies and prognostic biomarkers. This proposal tests the central hypothesis that epigenetic alterations at distal enhancer loci underlie metastatic competence in osteosarcoma. Based on the fundamental principle that gene enhancer elements determine cellular identity and are key in mediating cellular responses to exogenous stimuli, we mapped enhancer elements genome wide through ChIP-seq of enhancer-histone marks. Compared to non-metastatic progenitors, metastatic cells show somatic acquisition and loss of enhancer- histone marks at thousands of loci across the epigenome. We call these Metastatic Variant Enhancer Loci, or Met-VELs. Using a lung explant mouse model of pulmonary metastasis, we show that gained and lost Met-VELs converge on prometastatic transcriptional programs that are uniquely activated or repressed as the metastatic cells colonize the lung microenvironment. The findings suggest that an osteosarcoma cell's metastatic success depends on its capacity to dynamically activate and repress pro- and anti-metastatic genes in the lung microenvironment, and that this ability is encoded in the epigenome at the level of gene enhancer elements.
Aim 1 tests the hypothesis that Met-VELs are ubiquitous and predictive of metastatic transcription in osteosarcoma cell lines and in patient samples.
Aim 2 tests the hypothesis that Met-VEL gene activation and repression is driven by dynamic changes in the epigenetic state of enhancers and promoters, dictated by the tumor microenvironment.
Aim 3 tests the hypothesis that Met-VEL clusters define metastasis-dependency genes. Successful completion of these aims will provide conclusive evidence that osteosarcoma cells hijack enhancers to metastasize to the lungs, and could reveal commonalities among metastatic cells exploitable as therapeutic targets and prognostic biomarkers in human patients.

Public Health Relevance

Most cancer deaths result from spread of the primary tumor to distant sites, a process called metastasis. Patients with osteosarcoma are no exception. Despite the development of numerous treatment modalities targeting the primary tumor, 40% of osteosarcoma patients will succumb to metastatic progression. A major limitation in the development of targeted anti-metastatic therapies in osteosarcoma and other types of cancer is a lack of understanding of the biological drivers of this process. This study seeks to apply recent advances in the understanding of epigenetic regulation of cellular function to the study of tumor metastasis in osteosarcoma. Completion of the proposed studies will offer the potential for development of targeted therapies and prognostic biomarkers for osteosarcoma patients and may also provide insights to the molecular underpinnings of metastasis that will inform the study and treatment of other types of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Ault, Grace S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Schools of Medicine
United States
Zip Code
Ferguson, James; Devarajan, Mahima; DiNuoscio, Gregg et al. (2017) PRC2 is Dispensable in Vivo for ?-Catenin-Mediated Repression of Chondrogenesis in Mouse Embryonic Cranial Mesenchyme. G3 (Bethesda) :
Sahni, Jennifer M; Gayle, Sylvia S; Webb, Bryan M et al. (2017) Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 Is Targetable with BET Inhibitors. Cancer Res 77:5395-5408
Scacheri, Peter C; Tesar, Paul J (2017) iPSC Reprogramming Is Not Just an Open and Shut Case. Cell Stem Cell 21:711-712
Cohen, Andrea J; Saiakhova, Alina; Corradin, Olivia et al. (2017) Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nat Commun 8:14400
Corradin, Olivia; Cohen, Andrea J; Luppino, Jennifer M et al. (2016) Modeling disease risk through analysis of physical interactions between genetic variants within chromatin regulatory circuitry. Nat Genet 48:1313-1320
Merry, Callie R; McMahon, Sarah; Forrest, Megan E et al. (2016) Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer. Oncotarget 7:53230-53244
Morrow, James J; Mendoza, Arnulfo; Koyen, Allyson et al. (2016) mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo. Clin Cancer Res 22:6129-6141
Budnick, Isadore; Hamburg-Shields, Emily; Chen, Demeng et al. (2016) Defining the identity of mouse embryonic dermal fibroblasts. Genesis 54:415-30